Q1 2025 Earnings Estimate for Align Technology, Inc. Issued By William Blair (NASDAQ:ALGN)

Align Technology, Inc. (NASDAQ:ALGN) – William Blair upped their Q1 2025 earnings per share (EPS) estimates for shares of Align Technology in a research note issued on Wednesday, April 24th. William Blair analyst B. Vazquez now anticipates that the medical equipment provider will earn $1.93 per share for the quarter, up from their prior estimate of $1.78. The consensus estimate for Align Technology’s current full-year earnings is $7.69 per share. William Blair also issued estimates for Align Technology’s Q2 2025 earnings at $2.21 EPS, Q3 2025 earnings at $2.34 EPS and Q4 2025 earnings at $2.53 EPS.

ALGN has been the subject of several other reports. Stifel Nicolaus raised their price target on shares of Align Technology from $350.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 18th. The Goldman Sachs Group upped their price objective on shares of Align Technology from $197.00 to $225.00 and gave the stock a “sell” rating in a research report on Friday, February 2nd. Robert W. Baird lifted their target price on shares of Align Technology from $333.00 to $370.00 and gave the company an “outperform” rating in a research report on Thursday, April 25th. Piper Sandler restated an “overweight” rating and set a $375.00 price target (up previously from $355.00) on shares of Align Technology in a research report on Thursday, April 25th. Finally, Morgan Stanley lifted their price target on Align Technology from $344.00 to $360.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Align Technology presently has a consensus rating of “Moderate Buy” and an average price target of $353.00.

Align Technology Stock Down 1.4 %

ALGN stock opened at $304.82 on Monday. The stock has a 50-day simple moving average of $313.31 and a two-hundred day simple moving average of $271.08. Align Technology has a twelve month low of $176.34 and a twelve month high of $413.20. The firm has a market capitalization of $22.94 billion, a PE ratio of 50.22, a PEG ratio of 5.85 and a beta of 1.65.

Align Technology (NASDAQ:ALGN) last released its earnings results on Wednesday, January 31st. The medical equipment provider reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.13. The business had revenue of $956.73 million during the quarter, compared to the consensus estimate of $928.57 million. Align Technology had a return on equity of 14.15% and a net margin of 11.80%.

Insider Buying and Selling at Align Technology

In other Align Technology news, EVP Emory Wright sold 2,524 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $287.45, for a total value of $725,523.80. Following the transaction, the executive vice president now owns 709 shares in the company, valued at $203,802.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Align Technology news, Director Joseph Lacob sold 15,000 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $303.22, for a total transaction of $4,548,300.00. Following the transaction, the director now directly owns 131,994 shares of the company’s stock, valued at approximately $40,023,220.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Emory Wright sold 2,524 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $287.45, for a total transaction of $725,523.80. Following the transaction, the executive vice president now directly owns 709 shares in the company, valued at $203,802.05. The disclosure for this sale can be found here. Insiders sold 27,524 shares of company stock valued at $8,403,924 in the last quarter. Company insiders own 0.62% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. DAVENPORT & Co LLC grew its position in shares of Align Technology by 3.1% in the 3rd quarter. DAVENPORT & Co LLC now owns 2,172 shares of the medical equipment provider’s stock worth $663,000 after buying an additional 66 shares during the period. Asset Management One Co. Ltd. grew its stake in shares of Align Technology by 1.3% in the 3rd quarter. Asset Management One Co. Ltd. now owns 30,319 shares of the medical equipment provider’s stock worth $9,257,000 after buying an additional 387 shares during the last quarter. Handelsbanken Fonder AB increased its position in Align Technology by 3.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 32,348 shares of the medical equipment provider’s stock valued at $9,876,000 after buying an additional 936 shares in the last quarter. Ascent Wealth Partners LLC raised its stake in Align Technology by 16.4% during the third quarter. Ascent Wealth Partners LLC now owns 1,087 shares of the medical equipment provider’s stock valued at $332,000 after buying an additional 153 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in Align Technology by 9.4% in the third quarter. Commonwealth Equity Services LLC now owns 5,046 shares of the medical equipment provider’s stock worth $1,541,000 after acquiring an additional 435 shares in the last quarter. 88.43% of the stock is owned by hedge funds and other institutional investors.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.